Medications
| Subjects | 1465 |
| No LABA/ICS | 22 (1.5) |
| Inhaled corticosteroids only# | 136 (9.3) |
| <500 μg·day−1 | 21 (15.4) |
| 500–1000 μg·day−1 | 41 (30.1) |
| 1000–2000 μg·day−1 | 57 (41.9) |
| >2000 μg·day−1 | 15 (11) |
| LABAs only | 106 (7.2) |
| ICS/LABA combination# | 1326 (90.5) |
| <500 μg·day−1 | 62 (4.7) |
| 500–1000 μg·day−1 | 419 (31.6) |
| 1000–2000 μg·day−1 | 590 (44.5) |
| >2000 μg·day−1 | 253 (19.1) |
| Anticholinergic treatment | 498 (34) |
| Antileukotriene (montelukast) | 759 (52.2) |
| Long-term oral corticosteroid therapy | 245 (16.8) |
| Mean daily dose¶ mg | 19.4±34.2 |
| Anti-IgE (omalizumab) | 390 (26.8) |
| Dose mg | 347±155.3 |
| Frequency of treatment | |
| Every 2 weeks | 180 (46.9) |
| Every 4 weeks | 204 (53.1) |
| Missing data | 6 |
| Duration of treatment years | 3.1±2.6 |
| Theophylline | 97 (6.7) |
| Other therapies | |
| Long-term azithromycin | 84 (5.6) |
| Antihistamine | 655 (45) |
| Antidepressants | 121 (8.3) |
| β-blocker | 26 (1.8) |
| Anti-GORD | 483 (33.2) |
| Postmenopausal hormone therapy | 14 (1.5) |
| Desensitisation in the previous 5 years | 54 (3.7) |
| Alternative medicine | 84 (5.8) |
| Patient adherence level according to physician | |
| High | 1063 (78.5) |
| Medium | 245 (18.1) |
| Low | 47 (3.5) |
| Adherence level MMAS-4 score | 3.4±1 |
| Adherent patient (score=4) | 835 (64.8) |
| Non-adherent patients (score <4) | 454 (35.2) |
| Missing data | 78 |
Data are presented as n, n (%) or mean±sd. LABA: long-acting β2-agonist; ICS: inhaled corticosteroid; Ig: immunoglobulin; GORD: gastro-oesophageal reflux disease; MMAS-4: four-item Morisky Medication Adherence Assessment Scale. #: doses are presented as equivalent beclomethasone dipropionate; ¶: doses are presented as equivalent prednisolone.